MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Adult Solid Neoplasm|Recurrent Breast Carcinoma|Stage IV Breast Cancer
Interventions: DRUG: Akt Inhibitor MK2206|OTHER: Laboratory Biomarker Analysis|DRUG: Paclitaxel|OTHER: Pharmacological Study
Sponsor: National Cancer Institute (NCI)